Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1157]

ASCO 2022: Latest developments in mHSPC and mCRPC

Prof Heather Payne, Prof Kim Chi, Prof Laura-Maria Krabbe and Prof Kurt Miller

ASCO 2022: Latest developments in mHSPC and mCRPC ( Prof Heather Payne, Prof Kim Chi, Prof Laura-Maria Krabbe and Prof Kurt Miller )

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity...

Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma ( Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA )

Review: Best options in localised prostate cancer

Prof Eleni Efstathiou, Prof Oliver Sartor, Prof Kurt Miller and Prof Karim...

Review: Best options in localised prostate cancer ( Prof Eleni Efstathiou, Prof Oliver Sartor, Prof Kurt Miller and Prof Karim Fizazi )

Everolimus after surgery can improve outcomes in those with high-risk kidney...

Dr Christopher Ryan - OHSU Knight Cancer Institute, Portland, USA

Everolimus after surgery can improve outcomes in those with high-risk kidney cancer ( Dr Christopher Ryan - OHSU Knight Cancer Institute, Portland, USA )

Advance Prostate Cancer Consensus Conference 2021: Report

Prof Silke Gillessen and Prof Aurelius Omlin

Advance Prostate Cancer Consensus Conference 2021: Report ( Prof Silke Gillessen and Prof Aurelius Omlin )

ASCO GU 2022: Prostate roundup

Prof Eleni Efstathiou, Prof Axel Merseburger and Dr Neal Shore

ASCO GU 2022: Prostate roundup ( Prof Eleni Efstathiou, Prof Axel Merseburger and Dr Neal Shore )

Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid...

Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia

Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid tumours ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia )

PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1...

Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA

PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )

ASCO GU 2022: Latest in mHSPC

Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith

ASCO GU 2022: Latest in mHSPC ( Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith )

ASCO GU 2022: PARP inhibitors in prostate and MAGNITUDE

Dr Neal Shore and Prof Kim Chi

ASCO GU 2022: PARP inhibitors in prostate and MAGNITUDE ( Dr Neal Shore and Prof Kim Chi )

An AI-derived digital pathology-based biomarker to predict the benefit of ADT...

Prof Daniel Spratt - University Hospitals Seidman Cancer Center, Cleveland, USA

An AI-derived digital pathology-based biomarker to predict the benefit of ADT in PC with validation in NRG/RTOG 9408 ( Prof Daniel Spratt - University Hospitals Seidman Cancer Center, Cleveland, USA )

SG in combination with pembro in patients with mUC who progressed after...

Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA

SG in combination with pembro in patients with mUC who progressed after platinum (PLT)-based regimens ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )

More from ecancer